Aubrey Carhill is an Endocrinology/Metabolic physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 8 publications with 364 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blve
Houston, TX 770304009
Telephone
713-792-6161Provider last certified this registry record 5 Nov 2020.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20252 payments
- Abbott LaboratoriesProgram year20241 payment
- Intuity Medical IncProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
67.2%Insulin Analog22.3%Lantus Solostar43%Toujeo Solostar13%Novolog Flexpen13%Humalog Kwikpen U-10011%Basaglar Kwikpen U-1008%Tresiba Flextouch U-1004%Insulin Lispro Kwikpen U-1004%Levemir Flexpen4%Part D<11 patientsGLP-1 receptor agonist19.1%Ozempic70%Mounjaro25%Trulicity5%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
18.4%l-Thyroxine15.8%Levothyroxine Sodium88%Synthroid12%Part D≥49 patientsThyroid Hormone Synthesis Inhibitor1.8%Methimazole100%Part D<11 patients+ 1 more class in this area
Cardiovascular
12.5%Statin7.3%Atorvastatin Calcium75%Rosuvastatin Calcium13%Simvastatin12%Part D<11 patientsACE inhibitor2%Lisinopril100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987–2012
The Journal of Clinical Endocrinology & Metabolism
2015 - Abstract #1024: Riedel’s Thyroiditis in the Spectrum of Igg4-Related Systemic Disease
Endocrine Practice
2015 - The Noninvestigational Use of Tyrosine Kinase Inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring
The Journal of Clinical Endocrinology & Metabolism
2012
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”